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Patients with chemorefractory non-Hodgkin lymphomas generally have a poor prognosis. We used the
observational database of the Center for International Blood and Marrow Transplant Research to study the
outcome of 533 patients with refractory diffuse large B cell lymphoma (DLBCL) or grade III follicular
lymphoma (FL-III) who underwent allogeneic hematopoietic cell transplantation (allo-HCT) using either
myeloablative (MA; n ¼ 307) or reduced-intensity/nonmyeloablative conditioning (RIC/NST; n ¼ 226)
between 1998 and 2010. We analyzed nonrelapse mortality (NRM), relapse/progression, progression-free
survival (PFS), and overall survival (OS). Only 45% of the patients at transplantation had a Karnofsky
performance score of 90%. Median follow-up of surviving patients after MA and RIC/NST allo-HCT is 35
months and 30 months, respectively. At 3 years, MA allo-HCT was associated with a higher NRM compared
with RIC/NST (53% versus 42%; P ¼ .03), similar PFS (19% versus 23%; P ¼ .40), and lower OS (19% versus 28%;
P ¼ .02), respectively. On multivariate analysis, FL-III histology was associated with lower NRM (relative risk
[RR], .52), reduced risk of relapse/progression (RR, .42), and superior PFS (RR, .51) and OS (RR, .53), whereas
MA conditioning was associated with reduced risk of relapse/progression (RR, .66). Despite a refractory state,
a small subset of DLBCL and FL-III patients can attain durable remissions after allo-HCT. Conditioning regimen
intensity was not associated with PFS and OS despite a higher risk of relapse/progression with RIC/NST
allo-HCT.
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13.01.024are considered standard therapy for patients with relapsed,
chemosensitive diffuse large B cell lymphoma (DLBCL)
and appears to be curative for 40% to 45% of patients [1-3].
However, results of auto-HCT in high-risk patients with
relapsed aggressive non-Hodgkin lymphomas (NHLs)
with chemorefractory disease at the time of autografting
have been uniformly disappointing. Allogeneic HCT (allo-
HCT) is potentially a curative modality for a variety ofTransplantation.
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sive lymphomas [4-7]. The advantages of an allo-HCT
include a tumor-free graft and an allogeneic effect exerted
by donor T cells often referred to as graft-versus-lymphoma
effect.
Despite the higher risk of transplantation-related
morbidity and mortality with allo-HCT, select patients
with relapsed, aggressive NHL, especially a subgroup with
chemosensitive disease, can achieve long-term remissions
after allo-HCT [6,8-10]. Patients with aggressive NHL
refractory to salvage chemotherapy, however, have a poor
prognosis, and only limited data are available regarding the
outcomes after allo-HCT for this extremely high-risk group.
Moreover, the effects of regimen intensity, for example,
myeloablative (MA) conditioning versus reduced-intensity
conditioning (RIC) or nonmyeloablative conditioning
(NST) regimens, are not known. We report herein the
outcomes of allo-HCT in patients with chemorefractory,
aggressive B cell NHL relative to the intensity of the
transplantation conditioning regimens using the observa-
tional database of the Center for International Blood and
Marrow Transplant Research (CIBMTR). To date, this report
represents the largest study of refractory, aggressive NHL
patients undergoing allo-HCT.
METHODS
Data Sources
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry and the National Marrow Donor Program (NMDP)
established in 2004; both entities had been collecting data for more than 1
decade before the merger. This organization comprises a voluntary working
group of more than 450 transplantation centers worldwide that contribute
detailed data on consecutive auto- and allo-HCTs to a Statistical Center at the
Medical College of Wisconsin in Milwaukee, Wisconsin, and the NMDP
Coordinating Center in Minneapolis, Minnesota. Participating centers are
required to report all HCTs consecutively, with compliance monitored by on-
site audits. Patients are followed longitudinally, with yearly follow-up.
Computerized checks for discrepancies, physicians’ reviews of submitted
data, and on-site audits of participating centers ensure data quality.
Observational studies conducted by the CIBMTR are performed in compli-
ance with the Privacy Rule (Health Insurance Portability and Accountability
Act) as a public health authority and in compliance with all applicable
federal regulations pertaining to the protection of human research partici-
pants, as determined by continuous review of the Institutional Review
Boards of the NMDP and the Medical College of Wisconsin since 1985.
The CIBMTR collects data at two levels: Transplant Essential Data (TED)
and Comprehensive Report Form (CRF) data. TED data include disease type,
age, gender, pretransplantation disease stage and chemotherapy respon-
siveness, date of diagnosis, graft type (bone marrowederived and/or blood-
derived progenitor cells), conditioning regimen, posttransplantation
disease progression and survival, development of a new malignancy, and
cause of death. All CIBMTR teams contribute TED data. More detailed
disease and pre- and posttransplantation clinical information are collected
on a subset of registered patients selected for CRF data by a weighted
randomization scheme. TED and CRF level data are collected pre-
transplantation, 100 days, and 6 months posttransplantation and annually
thereafter or until death.
Subjects
The study population included all patients with aggressive, chemo-
refractory B cell NHL receiving an allo-HCT reported to the CIBMTR between
1998 and 2010. Eligible histologies included World Health Organization
grade III follicular lymphoma (FL-III) and DLBCL. Subjects included in our
analysis with primary refractory disease (ie, patients who never achieved
a complete remission or partial remission in response to any of the pre-HCT
therapies) at the time of allo-HCT were labeled as primary induction
failureeresistant, whereas patients with chemorefractory disease at the
time of allo-HCT, after a relapse from a prior remission, were labeled as
relapsed-resistant. Patients with indolent histologies (including grades I to II
FL) and those with transformed large cell lymphomas were not included.
Patients with evidence of chemosensitive disease (ie, patients achieving
a complete remission or partial remission) in response to the last line of
chemotherapy administered before allo-HCT were excluded. Pediatricpatients (n ¼ 5) and recipients of planned tandem auto-/allo-HCT (n ¼ 50),
syngeneic HCT (n ¼ 7), and umbilical cord blood transplantation (n ¼ 29)
were not included in the analysis. The patient- and disease-related variables
that are not reported for registration-only patients are indicated at appro-
priate places in Table 1.
Deﬁnitions
The intensity of conditioning regimens was categorized as MA or RIC/
NST using established consensus criteria [11]. Previously established
criteria for categorizing the degree of human leukocyte antigen (HLA)
matching were used [12] for unrelated donor transplantations. Well-
matched patients had either no identiﬁed HLA mismatching and infor-
mative data at four loci or allele matching at HLA-A, -B, and -DRB1 (6/6).
Partially matched pairs had a deﬁned, single-locus mismatch and/or
missing HLA data. Mismatched cases had at least two allele or antigen
mismatches.
Study Endpoints
Primary outcomes were nonrelapse mortality (NRM), progression/
relapse, progression-free survival (PFS), and overall survival (OS). NRM was
deﬁned as death from any cause during the ﬁrst 28 days after trans-
plantation or death without evidence of lymphoma progression/relapse;
relapsewas considered a competing risk. Progression/relapsewas deﬁned as
progressive lymphoma after HCT or lymphoma recurrence after a complete
remission; NRM was considered a competing risk. For PFS, a patient was
considered a treatment failure at the time of progression/relapse or death
from any cause. For relapse, NRM, and PFS, patients alive without evidence
of disease relapse or progression were censored at last follow-up. The OS
was deﬁned as the interval from the date of transplantation to the date of
death or last follow-up.
Other outcomes analyzed included acute and chronic graft-versus-host
disease (GVHD) and cause of death. Acute GVHD was deﬁned and graded
based on the pattern and severity of organ involvement using established
criteria [13]. Chronic GVHDwas deﬁned as the development of any evidence
of chronic GVHD based on clinical criteria [14]. Neutrophil engraftment was
deﬁned as ﬁrst of 3 successive days with absolute neutrophil
count .5  109/L after posttransplantation nadir. Platelet engraftment was
considered to have occurred on the ﬁrst of 3 consecutive days with platelet
count 20  109/L or higher, in the absence of platelet transfusion for 7
consecutive days. For engraftment and GVHD, death without the event was
considered a competing risk.
Statistical Analysis
Probabilities of PFS and OS were calculated using the Kaplan-Meier
product limit estimate. Probabilities of NRM, lymphoma progression/
relapse, acute and chronic GVHD, and engraftment were calculated using
cumulative incidence curves to accommodate for competing risks. Patient-,
disease- and transplantation-related factors were compared between RIC/
NST and MA groups using the chi-square test for categorical variables and
the Wilcoxon two-sample test for continuous variables. Associations among
patient-, disease-, and transplantation-related variables and outcomes of
interest were evaluated using multivariate Cox proportional hazards
regression. A stepwise selection multivariate model was built to identify
covariates that inﬂuenced outcomes. Covariates with a P < .05 were
considered signiﬁcant. The proportionality assumption for Cox regression
was tested by adding a time-dependent covariate for each risk factor and
each outcome. Covariates violating the proportional hazards assumption
were stratiﬁed in the Cox regression model. Results are expressed as relative
risk (RR) or the relative rate of occurrence of the event.
The following variables were reported for both registration-level and
research-level patients and were considered in multivariate analyses: age at
allo-HCT, gender, Karnofsky Performance Score (KPS) at allo-HCT, prior auto-
HCT, time interval between diagnosis and allo-HCT, histology (DLBCL versus
FL-III), disease status at allo-HCT, conditioning regimen intensity, donor
type, donorerecipient gender match, graft source, year of allo-HCT, and type
of GVHD prophylaxis.RESULTS
Patient-, Disease-, and Transplantation-Related
Variables
Between 1998 and 2010, 533 patients received allo-HCT
for refractory FL-III (n ¼ 80) and DLBCL (n ¼ 453); 307
patients received an MA allo-HCT and 226 received an RIC/
NST allo-HCT. Twelve DLBCL patients in the MA cohort were
included in a prior CIBMTR analysis [15]. Median follow-up of
Table 1
Characteristics of Patients Who Underwent Allogeneic Transplantation for
Chemorefractory Aggressive FL-III and DLBCL Reported to the CIBMTR
between 1998 and 2010
Variable Myeloablative RIC/NST P Value
Number of patients 307 226
Number of centers 85 59
Age, median (range), yr 46 (19-66) 53 (20-70) <.001
Sex .293
Male 185 (60) 126 (56)
Karnofsky score .590
<90% 156 (51) 135 (60)
Histology .001
FL-III 32 (10) 48 (21)
DLBCL 275 (90) 178 (79)
Prior auto-HCT 48 (15) 86 (38) <.001
Interval from auto-HCT to
allo-HCT, mo
13 (6-136) 17 (6-198) .149
Interval from diagnosis to
transplantation, mo
15 (1-238) 24 (5-340) <.001
Disease stage at diagnosis* .940
I-II 30 (34) 33 (34)
III-IV 54 (62) 58 (60)
Missing 3 (4) 6 (6)
B symptoms at any time before
transplantation*
.424
A 41 (47) 50 (52)
B 34 (39) 32 (33)
Missing 12 (14) 15 (15)
Lactate dehydrogenase at any
time before transplantation*
.986
Normal 32 (37) 34 (35)
Abnormal 53 (61) 56 (58)
Unknown 2 (2) 7 (7)
Number of prior chemotherapy
lines, median (range)
3 (1-5) 4 (1-5) .253
Bone marrow involvement at any
time before transplantation*
.900
No bone marrow involvement 46 (53) 46 (47)
Bone marrow involvment 21 (24) 22 (23)
Missing 20 (23) 29 (30)
Extranodal involvement at any
time before transplantation*
.507
No involvment 19 (22) 25 (26)
Involvment 68 (78) 71 (73)
Missing 0 1 (1)
Conditioning regimens* NA
CY/TBI 103 (50) 0
BU/CY 65 (31) 0
TBI low dose <500 cGY single
TBI < 800 cGY fract
0 7 (6)
Fludarabine/melphalan 0 30 (28)
Fludarabine/BU 0 21 (19)
TBI ¼ 200 cGY 0 14 (13)
Fludarabine þ TBI ¼ 200 cGY 0 9 (8)
Fludarabine þ CY 0 17 (16)
Fludarabine þ Ara-C þ ida 0 1 (1)
TBI  500 cGY single TBI  800
cGY fract
17 (8) 0
Melphalan > 150 mg/m2 7 (3) 0
BU > 9 mg/kg 11 (5) 0
BU þ melphalan 5 (3) 0
CBV/similar 0 10 (9)
CNS involvement at any time
before transplantation*
.381
No CNS 84 (97) 90 (93)
CNS 3 (3) 6 (6)
Missing 0 1 (1)
Bulky disease* .571
<5 cm 18 (21) 22 (23)
5 cm 26 (30) 25 (26)
Missing 43 (49) 50 (51)
Radiation before transplantation* .244
No 20 (23) 19 (20)
Yes 32 (37) 48 (49)
Missing 35 (40) 30 (31)
(continued)
Table 1
(continued)
Variable Myeloablative RIC/NST P Value
Rituximab before transplantation* .122
Rituximab 57 (59) 80 (70)
No rituximab 39 (41) 35 (30)
Disease status .005
PIF-resistant 159 (52) 89 (39)
REL-resistant 148 (48) 137 (61)
Graft type .008
Bone marrow 65 (21) 28 (12)
Peripheral blood 242 (79) 198 (88)
Type of donor* .090
HLA-id sibling 162 (60) 94 (47)
Other relative 16 (6) 13 (7)
URD well-matched 64 (23) 62 (31)
URD partially matched 20 (7) 23 (12)
URD mismatched 10 (4) 8 (4)
Year of transplantation .002
1998-2001 86 (28) 35 (15)
2002-2005 88 (29) 82 (36)
2006-2010 133 (43) 109 (48)
ATG* <.001
ATG alone 12 (14) 24 (25)
Alemtuzumab alone 0 13 (14)
No ATG or alemtuzumab 75 (26) 59 (61)
GVHD prophylaxis .107
Ex vivo T cell depletion 10 (3) 3 (1)
Tacrolimus  others 168 (55) 119 (53)
Cyclosporine  others 105 (34) 88 (39)
CD34 selection 6 (2) 0
Others, not speciﬁed 18 (6) 16 (7)
Median FU of survivors (range),
mo
35 (3-122) 30 (3-110)
ATG indcates antithymocyte globulin; BU, busulfan; CMV, cytomegalovirus;
CNS, central nervous system; CY, cyclosphosphamide; HLA-id, human
leukocyte antigen-identical; R, recipient; PIF, primary induction failure; REL,
relapsed; MTX, methotrexate; TBI, total body irradiation; URD, unrelated
donor.
* Research-level patients only.
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and 30 months, respectively. Completeness of follow-up at 3
years was 80% in both groups, reﬂecting good follow-up to
this time point [16]. Table 1 describes patient-, disease-, and
transplantation related variables of two cohorts (MA versus
RIC/NST) analyzed. The RIC/NST cohort was older compared
with MA cohort (median age, 53 years versus 46 years,
respectively; P < .001). Only 242 patients (45%) had a pre-
transplantation KPS of 90 or higher. Median time from
diagnosis to transplantation was signiﬁcantly longer in the
RIC/NST group compared with the MA cohort (24 months
versus 15 months, respectively; P < .001).
No signiﬁcant difference at baseline was observed
between the 2 groups in terms of disease stage at diagnosis, B
symptoms, number of lines of prior therapy, bone marrow or
extranodal involvement, disease bulk, central nervous
system involvement, prior rituximab use, and donor type.
Signiﬁcantly more patients in the RIC/NST group had a prior
history of undergoing an auto-HCT (38% versus 15%; P< .001)
and received a peripheral blood allograft (88% versus 79%;
P ¼ .008). More patients in the MA group had primary
refractory disease (primary induction failureeresistant) (52%
versus 39%; P ¼ .005). The most common conditioning
regimens before MA allo-HCT were cyclophosphamide/total
body irradiation and busulfan/cyclophosphamide. Most
patients (w90%) in both cohorts received calcineurin
inhibitor-based GVHD prophylaxis.
Table 2
Univariate Outcome Probabilities
Outcome event Myeloablative RIC/NST P Value*
n Prob
(95% CI)
n Prob
(95% CI)
Time to ANC
> .5  109/L
245 189
28 d 85 (80-89) 90 (85-94) .085
100 d 86 (81-90) 92 (87-95) .047
Platelet recovery
 20  109
171 146
28 d 54 (46-61) 79 (71-85) <.001
100 d 71 (63-77) 87 (80-92) <.001
Acute GVHD (II-IV) 225 183
100 d 29 (24-35) 31 (25-38) .684
Chronic GVHD 229 179
1 y 33 (27-39) 38 (31-45) .274
3 y 37 (31-43) 39 (32-46) .619
NRM 289 218
100 d 38 (32-43) 25 (20-31) .004
1 y 47 (41-53) 36 (30-43) .017
3 y 53 (46-59) 42 (35-49) .034
Relapse/progression 289 218
1 y 27 (22-33) 32 (26-39) .289
3 y 28 (23-34) 35 (28-42) .124
PFS 289 218
1 y 26 (20-31) 32 (25-38) .138
3 y 19 (15-25) 23 (17-30) .408
OS 307 226
1 y 31 (25-36) 41 (34-47) .016
3 y 19 (15-24) 28 (22-35) .027
ANC indicates absolute neutrophil count; Prob, probability.
* Probabilities of neutrophil and platelet recovery, platelet recovery,
acute GVHD, chronic GVHD, treatment-related mortality, and progression/
relapse were calculated using the cumulative incidence estimate. PFS and
OS were calculated using the Kaplan-Meier product limit estimate.
Table 3
Multivariate Analysis for NRM, Progression/Relapse, PFS, and OS (Follicular/
DLBCL)
Variables n RR (95% CI) P Value
Treatment-related mortality
Main effect
RIC/NST 202 1 .113
Myeloablative 264 1.25 (.95-1.66)
Histology
DLBL 393 1 .002
Follicular 73 .52 (.35-.79)
Donor type
Unrelated 217 1 .003
Related 249 .64 (.48-.86)
Progression/relapse
Main effect
RIC/NST 202 1 .015
Myeloablative 264 .66 (.47-.92)
Histology
DLBL 393 1 .002
Follicular 73 .42 (.25-.73)
Prior autologous transplant
No prior auto 365 1 Poverall ¼ .006
Prior auto, 12 m 39 .90 (.49-1.65) .742
Prior auto, >12 m 62 .30 (.15-.63) .001
Contrast: 12 versus >12 2.99 (1.22-7.35) .017
PFS
Main effect
RIC/NST 202 1 .843
Myeloablative 264 1.02 (.83-1.27)
Histology
DLBL 393 1 <.001
Follicular 73 .51 (.37-.70)
OS
Main effect
RIC/NST 226 1 .220
Myeloablative 307 1.14 (.93-1.40)
Histology
DLBL 453 1 <.001
Follicular 80 .53 (.39-.72)
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Univariate analysis of patient outcomes after HCT is
shown in Table 2, whereas multivariate analysis for NRM,
relapse/progression, PFS, and OS are summarized in Table 3.
Engraftment and GVHD
The cumulative incidence of neutrophil engraftment at
day þ28 was 85% in the MA cohort and 90% in the RIC/NST
cohort (P ¼ .08) (Table 2). The cumulative incidence of
platelet recovery at day þ28 was signiﬁcantly higher after
RIC/NST compared with MA conditioning (79% versus 54%;
P< .001). Cumulative incidence of grades II to IV acute GVHD
at day þ100 was 29% and 31% in MA and RIC/NST groups
(P ¼ .68), respectively (Table 2). Cumulative incidence of
chronic GVHD at 1 year posttransplantation in similar order
was 33% and 38%, respectively (P ¼ .27).
Nonrelapse mortality
Cumulative incidence of NRM was signiﬁcantly lower in
the RIC/NST cohort versus the MA cohort, both at 100 days
(RIC/NST 25% [95% conﬁdence interval {CI}, 20 to 31] versus
MA 38% [95% CI, 32 to 43], P ¼ .004) and at 3 years (RIC/NST
42% [95% CI, 35 to 49] versus MA 53% [95% CI, 46 to 59],
P ¼ .03). However, on multivariate analysis, conditioning
regimen intensity was no longer associated with NRM
(versus RIC/NST; RR, 1.25; 95% CI, .94 to 1.65) (Table 3). FL-III
histology (RR¼ .52; 95% CI; .35 to .79; P¼ .002) andmatched
related donor (MRD) allo-HCT (RR, .64; 95% CI; .48 to .86;
P ¼ .003) were associated with a reduced risk of NRM in
multivariate analysis. Separate multivariate analysis for
patients previously not undergoing an auto-HCT similarly
showed reduced risk of NRM with FL-III (RR, .44; 95% CI; .27to .74) and MRD transplantation (RR, .72; 95% CI, .51 to 1.00).
Multivariate analysis of DLBCL patients only (by excluding
FL-III) also showed association of MRD with reduced risk of
NRM (RR, .65; 95% CI, .48 to .89).
Relapse/progression
The 1- and 3-year probability of relapse/progression
were similar in both the MA and the RIC/NST groups
(Table 2); at 3 years, it was 28% in the MA cohort (95% CI, 23
to 34) and 35% in the RIC/NST cohort (95% CI, 28 to 42;
P ¼ .12). On multivariate analysis, MA conditioning (RR, .66;
95% CI, .47 to .92; P ¼ .02), FL-III histology (RR, .42; 95% CI,
.25 to .73; P ¼ .002), and a prior auto-HCT more than 12
months before the allo-HCT compared with no prior auto-
HCT (RR, .30; 95% CI, .15 to .63; P ¼ .001) were associated
with a reduced risk of relapse/progression (Table 3). Sepa-
rate multivariate analysis for patients previously not
undergoing an auto-HCT similarly showed a reduced risk of
relapse/progression with FL-III (R ¼ .39; P ¼ .002). Multi-
variate analysis of DLBCL patients only showed an associa-
tion of a prior auto-HCT more than 12 months before the
allo-HCT, with reduced risk of relapse/progression (RR, .27;
P ¼ .002).
Progression-free survival
PFS estimates were not signiﬁcantly different between
MA and RIC/NST groups, neither at 1 year (26% [95% CI, 20 to
31] versus 32% [95% CI, 25 to 38], P ¼ .13) nor at 3 years (19%
[95% CI, 15 to 25] versus 23% [95% CI, 17 to 30], P ¼ .40)
(Figure 1, Table 2). On multivariate analysis, FL-III (RR, .51;
Figure 1. Kaplan-Meier estimates of adjusted OS after allogeneic trans-
plantation for FL-III and DLBCL
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PFS compared with DLBCL (Table 3). Separate multivariate
analysis for patients previously not undergoing an auto-HCT
also showed that only FL-III was associated was superior
PFS (RR ¼ .43, P < .0001), whereas in the multivariable
analysis for DLBCL patients only, none of the variables was
signiﬁcant.
Overall survival
In univariate analysis, the RIC/NST group had superior OS
at 1 year (41% [95% CI, 34 to 47] versus 31% [95% CI, 25 to 36];
P¼ .01) and at 3 years (28% [95% CI, 22 to 35] versus 19% [95%
CI, 15 to 24]; P ¼ .02) compared with the MA group (Table 2).
On multivariate analysis, only FL-III (RR, .53; 95% CI, .39 to
.72; P < .0001) was associated with a reduced risk of death
after allo-HCT (Figure 1, Table 3). Separate multivariate
analysis for patients previously not undergoing an auto-HCT
also showed that only FL-III was associated with reduced risk
of death (RR ¼ .40, P < .0001), whereas in the multivariable
analysis for DLBCL patients only, none of the variables was
signiﬁcant.
Causes of death
Most deaths, 104 in the MA cohort and 77 in the RIC/NST
cohort, were attributed to disease relapse and/or progres-
sion. Causes of death are summarized in Table 4.
DISCUSSION
The aims of the present study were to deﬁne outcomes of
chemorefractory DLBCL and FL-III patients after allo-HCT,Table 4
Causes of Death
Cause of death Myeloablative RIC/NST
Total number 241 162
Graft rejection 0 1 (1)
Infection 31 (13) 18 (11)
Pulmonary syndrome 4 (2) 4 (2)
ARDS 6 (2) 0
GVHD 13 (5) 14 (9)
Primary disease 104 (43) 77 (48)
Organ failure 26 (11) 11 (7)
Second malignancy 1 (<1) 0
Hemorrhage 4 (2) 2 (1)
Vascular 1 (<1) 1 (1)
Toxicity 5 (2) 1 (1)
Other cause, not speciﬁed* 46 (19) 33 (20)
ARDS indicates adult respiratory distress syndrome.
* Twenty-nine cases reported “other HSCT-related cause.”relative to the intensity of the conditioning regimens and
other variables, including graft source and prior use of auto-
HCT. This large cohort of refractory aggressive lymphoma
patients gleaned from multiple centers provides several
important observations. First, despite refractory disease at
baseline, approximately one-fourth of aggressive NHL
patients undergoing allo-HCT are alive and in remission 3
years posttransplantation. Second, although use of MA allo-
HCT in this poor-prognosis group reduced the relapse risk,
OS (on univariate analysis) was inferior, likely due to the
unacceptably high rates of NRM. Third, histologic subtype
emerges as a major predictor of transplantation outcomes,
with refractory FL-III consistently showing better outcomes
compared with DLBCL; this ﬁnding emphasizes the impor-
tance of different disease biology of these subtypes. Fourth,
high NRM rates after allo-HCT in this high-risk group will
continue to be the main barrier toward wider application of
this modality.
Limited data have been published on the role of allo-HCT
in patients with refractory aggressive B cell NHL. Registry
data from the European Group for Blood and Bone Marrow
Transplantation on outcomes of RIC allo-HCT in patients
with NHL (including indolent and aggressive histologies)
identiﬁed aggressive histology and chemorefractory disease
as predictors of inferior outcomes but included only 13
refractory aggressive lymphoma patients [17]. French [10]
and Japanese [8] registry data reported OS rates of w40%
with allografting in aggressive NHL, but these studies
included a small number of patients with refractory disease
(n¼ 27 in the French study and a number of B cell aggressive
NHL not reported in the Japanese study), whose outcomes
were not reported separately. Further, a single institution
reported 5-year survival rates of approximately 35% in 46
refractory aggressive NHL patients undergoing allo-HCT;
most of these subjects received MA conditioning [18].
Finally, a retrospective analysis from the United Kingdom of
17 refractory DLBCL patients receiving RIC allo-HCT showed
a disappointing 3-year OS/PFS of only 12% [7]. Our study, the
largest report to date, indicates that a small subset of
refractory FL-III/DLBCL patients (w25%) can survive long-
term after allo-HCT. It is, however, important to interpret
these numbers in the context of dismal long-term prognosis
of these patients with standard chemotherapies and in light
of the fact that only some patients in our study at trans-
plantation had good KPS.
Despite the reduced risk of relapse/progression, we note
that MA allo-HCT was not associated with improved survival
outcomes, potentially due to high NRM rates of 53% at 3
years. Our report is not a randomized comparison of high-
versus low-intensity conditioning regimens. We cannot
discount inherent selection bias (ie, a tendency of trans-
plantation physicians to preferentially offer MA allo-HCT to
patients with “higher risk” or primary refractory disease).
The time interval between diagnosis and allo-HCT was
shorter in the MA cohort, compared with the RIC/NSTcohort,
which might be a surrogate marker of more aggressive
disease biology of patients included in the former group.
However, the distribution of other potentially adverse
prognostic factors (eg, bulky disease, bone marrow involve-
ment, extranodal disease, and lines of prior therapy across
these two cohorts) appears to be balanced at baseline in our
study. Hematologic engraftment in the RIC/NST cohort
appears more robust, likely reﬂecting more frequent use of
peripheral blood rather than bone marrow as an allogeneic
graft source in this setting.
Figure 2. Kaplan-Meier estimates of adjusted PFS after allogeneic trans-
plantation for FL-III and DLBCL.
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NHL who are refractory to conventional therapies, esca-
lating the intensity of conditioning regimens is unlikely to
improve patient outcomes. The RIC/NST group in our study
is heterogeneous and represents a spectrum of conditioning
regimens ranging from truly NST approaches to nearly
ablative regimens. However, the relatively small number
of patients receiving a truly NST allo-HCT (2-Gy total
body irradiation ¼ 14, ﬂudarabine/2-Gy total body
irradiation ¼ 9) in our study precludes us from assessing the
relative risk and beneﬁts of NST versus RIC allo-HCT in
refractory B cell NHL.
The NRM rates we observed for the RIC/NST cohort are
higher than the rates generally reported for indolent
lymphomas [19,20]; however, in the subset of chemo-
refractory-indolent lymphomas, NRM rates approaching 50%
to 60% have been previously reported [21,22]. One-third of
the RIC/NST patients in our study previously received an
auto-HCT, a potential reason for high NRM. On multivariate
analysis, however, a prior auto-HCT was not associated with
higher NRM, and other investigators also have not consis-
tently found a prior auto-HCT to signiﬁcantly inﬂuence NRM
after the allogeneic procedure in DLBCL [6,7]. Moreover,
separate multivariable analyses in our study performed by
excluding patients who underwent prior auto-HCT showed
ﬁndings in line with the multivariable analyses of the entire
study population.
Nonetheless, it is clear that mitigating NRM rates in
this high-risk group by developing novel conditioning
approaches, designed to provide better disease control
and acceptable NRM rates while permitting the graft-
versus-lymphoma effect to emerge posttransplantation, is
urgently needed. Along these lines, Gopal et al. [23] reported
a 30-month 54% survival with an NRM rate of 16% with
radioimmunotherapy-based NST in a cohort of mostly
refractory B cell NHL patients, ﬁndings similar to those of
Bethge and coworkers [24]. Our data also hint that in the
context of refractory lymphoma patients, availability of an
MRD might predict reduced rates of NRM after allo-HCT.
Our report included both registration- and research-level
patients reported to CIBMTR. The primary objective of this
study was to describe transplantation outcomes of chemo-
refractory DLBCL and FL-III patients. Missing variables in
registration-level patients include disease stage at diagnosis,
bulky disease status, B symptoms, lactate dehydrogenase
level, bone marrow involvement, and extranodal involve-
ment at any time point before allo-HCT. Although some of
these variables (eg, lactate dehydrogenase level before allo-
HCT) are prognostic [9,25], the signiﬁcance of their pres-
ence at any time point before transplantation (as opposed to
their presence at the time of transplantation) in a cohort of
exclusively chemotherapy-refractory patients is not known.
The fact that data about key variables of interest, such as
disease status at transplantation, intensity of conditioning
regimens, donor type, graft source, KPS, history of prior
autografting, and all posttransplantation outcomes of
interest (engraftment, GVHD, NRM, OS, PFS, etc.), were
available on both registration- and research-level patients
supported our decision to include both patient populations.
Another possible limitation of our report is the lack of
information about functional imaging (ie, positron emission
tomography [PET] or PET/computed tomography scan
results) before allo-HCT. Some patients included in this
study underwent transplantation in the pre-PET era. Even
in patients who underwent transplantation in the timeperiod when PET scans became widely available, this
imaging modality was likely not uniformly performed in all
patients before allo-HCT. Moreover, information about
functional imaging is not available for registration-level
patients, and the criteria used to uniformly report and
interpret response rates using PET scans were not purposed
until 2007 [26]. However, wherever available, patients with
a negative PET scan result before allo-HCT were considered
chemosensitive for CIBMTR reporting purposes and were
not included in the current study.
A noteworthy ﬁnding of our study is the relatively
encouraging outcomes of FL-III patients after allo-HCT
despite refractory disease. The 3-year PFS of FL-III patients
in our study after MA and RIC/NST was 41% and 40%,
respectively (Figure 2). The 3-year OS in similar order was
42% and 51%, respectively. Vose and colleagues [27] reported
that this population is not likely to achieve long-term
remissions with auto-HCT. We decided to include FL-III
patients in addition to DLBCL in our report to highlight the
fact that although these patients may not achieve durable
remissions with auto-HCT, this is not necessarily true after
allo-HCT. Our encouraging data support examining the role
of allo-HCT in refractory FL-III, prospectively. Whether the
outcomes of refractory grade IIIa FL are different from grade
IIIb FL after allo-HCT is not known. These data are unfortu-
nately not captured in CIBMTR reporting forms. RIC/NSTallo-
HCT in aggressive histologies has been associated with
a higher risk of relapse compared with more indolent vari-
eties [9]. Within the context of refractory aggressive histol-
ogies, the lower relapse rates of FL-III compared with DLBCL
are intriguing and illustrate the different disease biologies of
these two subtypes.
To use our data for decision making in the clinic, it is
important to interpret these results in the context of
outcomes of relapsed DLBCL with other available treatment
modalities. In general, consolidation with auto-HCT clearly
remains the standard option for relapsed and chemo-
sensitive DLBCL, even in the chemoimmunotherapy (CIT) era
[3]. For those DLBCL patients who relapse after an auto-HCT
but remain sensitive to salvage chemotherapies, RIC/NST
allo-HCT is routinely offered by many centers based on
encouraging outcomes (OS, 45% to 50%; PFS, 35% to 45%)
reported by many groups [5-7,28]. The best therapeutic
option for chemorefractory DLBCL patients is more contro-
versial. In the pre CIT era, van Besien et al. [29] initially
showed that a small subset of such refractory aggressive NHL
patients (w20%) could survive disease-free after allo-HCT.
Observations by others [30], however, suggested that
a similar degree of disease control in refractory DLBCL
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PFS ¼ 19.4%). It is important to point out, however, that the
outcomes of chemorefractory DLBCL after auto-HCT in a large
CIBMTR study were disappointing, with only 7 of 52
chemotherapy-resistant patients (13%) surviving disease-
free 2 years after HCT [31]. Similarly, the outcomes of che-
morefractory DLBCL patients in the CIT era with [3,32] or
without [3] auto-HCT have been generally poor (3-year
PFS < 10% to 15%). In contrast, the 20% to 25% 3-year PFS of
refractory aggressive NHL patients in our study has been
consistently seen in other reports that included a small
subset of refractory patients [7,15,33]. Hence, it appears
unlikely that in the CIT era, salvage chemotherapies with or
without auto-HCT can provide durable disease control in
refractory DLBCL. For such refractory DLBCL patients, espe-
cially for the subset with an available MRD, RIC/NST allo-HCT
should be considered a valid option.
In conclusion, our analysis of this large set of registry data
shows that a subset of chemorefractory FL-III and DLBCL
patients can have durable remissions after allo-HCT. MA
conditioning does not provide superior survival outcomes
compared with RIC/NST allo-HCT. Although refractory,
aggressive NHL patients are best managed on a clinical trial,
in the absence of a protocol therapy option, consideration of
an allograft appears to be a viable option for NHL patients
who have disease refractory to conventional therapies.
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